← All trials
NCT06134362
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2024
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Nov 18, 2023
- Last posted
- Nov 27, 2023
- Enrollment
- 3500
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ViiV HealthcareLead sponsor
- PPDCollaborator
- GlaxoSmithKlineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.